Free Trial
NASDAQ:IXHL

Incannex Healthcare (IXHL) Stock Price, News & Analysis

Incannex Healthcare logo
$0.64 -0.04 (-5.44%)
Closing price 04/2/2025 03:56 PM Eastern
Extended Trading
$0.65 +0.01 (+1.09%)
As of 08:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Incannex Healthcare Stock (NASDAQ:IXHL)

Key Stats

Today's Range
$0.63
$0.70
50-Day Range
$0.64
$2.21
52-Week Range
$0.63
$3.55
Volume
36,399 shs
Average Volume
38,485 shs
Market Capitalization
$11.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Healthcare Inc. was incorporated in 2001 and is based in Sydney, Australia.

Remove Ads

Incannex Healthcare Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
7th Percentile Overall Score

IXHL MarketRank™: 

Incannex Healthcare scored higher than 7% of companies evaluated by MarketBeat, and ranked 873rd out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Incannex Healthcare.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Incannex Healthcare is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Incannex Healthcare is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Incannex Healthcare has a P/B Ratio of 12.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Incannex Healthcare's valuation and earnings.
  • Percentage of Shares Shorted

    0.36% of the float of Incannex Healthcare has been sold short.
  • Short Interest Ratio / Days to Cover

    Incannex Healthcare has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Incannex Healthcare has recently increased by 1.03%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Incannex Healthcare does not currently pay a dividend.

  • Dividend Growth

    Incannex Healthcare does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.36% of the float of Incannex Healthcare has been sold short.
  • Short Interest Ratio / Days to Cover

    Incannex Healthcare has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Incannex Healthcare has recently increased by 1.03%, indicating that investor sentiment is decreasing.
  • Search Interest

    2 people have searched for IXHL on MarketBeat in the last 30 days.
  • MarketBeat Follows

    1 people have added Incannex Healthcare to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Incannex Healthcare insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    26.53% of the stock of Incannex Healthcare is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 0.43% of the stock of Incannex Healthcare is held by institutions.

  • Read more about Incannex Healthcare's insider trading history.
Receive IXHL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Incannex Healthcare and its competitors with MarketBeat's FREE daily newsletter.

IXHL Stock News Headlines

Trump’s Final Plan
Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’s secret plan to trigger the greatest transfer of wealth since FDR and LBJ – trillions of dollars could be redistributed.
See More Headlines

IXHL Stock Analysis - Frequently Asked Questions

Incannex Healthcare's stock was trading at $2.12 at the start of the year. Since then, IXHL shares have decreased by 69.7% and is now trading at $0.6430.
View the best growth stocks for 2025 here
.

Incannex Healthcare Inc. (NASDAQ:IXHL) issued its quarterly earnings data on Friday, February, 14th. The company reported ($0.33) earnings per share for the quarter. The company had revenue of $10 billion for the quarter.

Shares of IXHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Incannex Healthcare investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), e.l.f. Beauty (ELF), Disc Medicine (IRON) and Jabil (JBL).

Company Calendar

Last Earnings
2/14/2025
Today
4/03/2025
Next Earnings (Estimated)
5/21/2025
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:IXHL
Fax
N/A
Employees
3
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-18,460,000.00
Pretax Margin
-24,261.22%

Debt

Sales & Book Value

Annual Sales
$98,000.00
Price / Cash Flow
N/A
Book Value
$0.05 per share
Price / Book
12.86

Miscellaneous

Free Float
13,122,000
Market Cap
$11.48 million
Optionable
Not Optionable
Beta
7.49
10 Stocks Set to Soar in Spring 2025 Cover

Market volatility creates opportunity. Our analysts have pinpointed 10 stocks perfectly positioned for exceptional growth this spring, even amid economic uncertainty. Don't miss your chance to access this timely research and invest with confidence.

Get This Free Report

This page (NASDAQ:IXHL) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners